Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867943 | 0.89 | MGLL (0.50) | MGLLGPR119STSKDM1AMAPT | |
| SCHEMBL29469965 | 0.89 | MGLL (0.50) | MGLLGPR119STSKDM1AMAPT | |
| SCHEMBL29470023 | 0.88 | MGLL (0.58) | MGLLGPR119KDM1A | |
| SCHEMBL23868006 | 0.88 | MGLL (0.58) | MGLLGPR119KDM1A | |
| SCHEMBL2345498 | 0.86 | MGLL (0.46) | MGLLGPR119STS | |
| SCHEMBL23867873 | 0.86 | MGLL (0.53) | MGLLMEN1KMT2AGPR119TP53 | |
| SCHEMBL29469959 | 0.86 | MGLL (0.53) | MGLLMEN1KMT2AGPR119TP53 | |
| SCHEMBL23868051 | 0.86 | ALDH1A1 (0.54) | MGLLGPR119ALDH1A1STSHTT | |
| SCHEMBL2344535 | 0.86 | DRD2 (0.47) | MGLLGPR119 | |
| SCHEMBL23868000 | 0.85 | MGLL (0.59) | MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362153-B | Azaspiro compounds as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-20 | — | — | US | disclosed |
| US-11505546-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-22 | — | — | US | disclosed |
| US-20220081428-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-17 | — | — | US | disclosed |
| US-20220081428-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-17 | — | — | US | disclosed |
| WO-2021191390-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | MGLL 1/4885MEN1 2371/4885KMT2A 2146/4885 |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | MGLL 1/4885MEN1 2401/4885KMT2A 1464/4885 |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPAR1, LPL | MGLL 1/4885MEN1 2401/4885KMT2A 1464/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | MGLL 298/4885MEN1 1724/4885KMT2A 717/4885 |
| US-20220081428-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPAR1, LPL | MGLL 1/4885MEN1 2401/4885KMT2A 1464/4885 |
| US-11505546-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | MGLL 1/4885MEN1 2401/4885KMT2A 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.